Compare TOUR & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | ASRT |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.3M | 76.0M |
| IPO Year | 2014 | 2004 |
| Metric | TOUR | ASRT |
|---|---|---|
| Price | $0.67 | $18.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 120.6K | ★ 144.1K |
| Earning Date | 03-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | $9.93 | N/A |
| Revenue Next Year | $10.81 | $16.87 |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.51 |
| 52 Week High | $1.01 | $20.45 |
| Indicator | TOUR | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 70.05 |
| Support Level | $0.74 | $0.69 |
| Resistance Level | $0.79 | $20.45 |
| Average True Range (ATR) | 0.05 | 1.41 |
| MACD | 0.00 | 0.26 |
| Stochastic Oscillator | 59.08 | 79.35 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.